Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Quality of Life in Patients With Metastatic Prostate Cancer Following Treatment With Cabazitaxel Versus Abiraterone or Enzalutamide (CARD): An Analysis of a Randomised, Multicentre, Open-Label, Phase 4 StudyLancet Oncol 2020 Sep 11;[EPub Ahead of Print], K Fizazi, G Kramer, JC Eymard, CN Sternberg, J de Bono, D Castellano, B Tombal, C Wülfing, M Liontos, J Carles, R Iacovelli, B Melichar, Á Sverrisdóttir, C Theodore, S Feyerabend, C Helissey, S Oudard, G Facchini, EM Poole, A Ozatilgan, C Geffriaud-Ricouard, S Bensfia, R de Wit
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.